Acute zonal occult outer retinopathy
| Acute zonal occult outer retinopathy | |
|---|---|
| Synonyms | AZOOR |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Sudden onset of visual field loss, photopsia |
| Complications | Vision loss |
| Onset | Sudden |
| Duration | Variable |
| Types | N/A |
| Causes | Unknown |
| Risks | Possible association with autoimmune disease |
| Diagnosis | Visual field test, Electroretinography |
| Differential diagnosis | Retinitis pigmentosa, Multiple evanescent white dot syndrome |
| Prevention | N/A |
| Treatment | No established treatment, corticosteroids sometimes used |
| Medication | N/A |
| Prognosis | Variable, some cases stabilize, others progress |
| Frequency | Rare |
| Deaths | N/A |
A rare retinal disease affecting vision
Acute zonal occult outer retinopathy (AZOOR) is a rare retinal disorder characterized by sudden onset of visual field loss, often accompanied by photopsia, or the perception of flashing lights. The condition primarily affects young to middle-aged adults and is more prevalent in females. AZOOR is part of a group of retinal diseases known as the "AZOOR complex," which also includes acute macular neuroretinopathy, acute idiopathic blind spot enlargement, and multifocal choroiditis.
Pathophysiology[edit]
The exact cause of AZOOR is not well understood, but it is believed to involve an inflammatory process affecting the outer retina, particularly the photoreceptor layer. The disease may be associated with viral infections or autoimmune responses, although no specific pathogen has been consistently identified. The condition is characterized by the loss of photoreceptors in one or more zones of the retina, leading to the characteristic visual field defects.
Clinical Presentation[edit]
Patients with AZOOR typically present with sudden onset of visual disturbances, which may include:
- Loss of visual field in one or both eyes
- Photopsia (flashing lights)
- Decreased visual acuity
- Metamorphopsia (distorted vision)
The visual field loss is often described as a "zonal" defect, affecting specific areas of the visual field while sparing others. The condition can be unilateral or bilateral, and the severity of symptoms can vary widely among patients.
Diagnosis[edit]
The diagnosis of AZOOR is primarily clinical, based on the patient's symptoms and the characteristic appearance of the retina on examination. Diagnostic tests that may be used to support the diagnosis include:
- Visual field tests to map the extent of visual field loss
- Optical coherence tomography (OCT) to assess the integrity of the retinal layers
- Electroretinography (ERG) to evaluate retinal function, often showing reduced or absent responses in affected areas
- Fluorescein angiography to rule out other retinal vascular conditions
Management[edit]
There is no specific treatment for AZOOR, and management is primarily supportive. Some patients may experience spontaneous improvement in their symptoms, while others may have persistent visual field defects. Treatment options that have been explored include:
- Corticosteroids to reduce inflammation
- Immunosuppressive therapy in cases suspected to have an autoimmune component
- Antiviral medications if a viral etiology is suspected
Prognosis[edit]
The prognosis for patients with AZOOR varies. Some individuals may experience partial or complete recovery of vision, while others may have permanent visual field defects. The condition can be stable or progressive, and long-term follow-up is often necessary to monitor changes in vision.
Related pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian